Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

Rationale Data from a phase 2/3 North American clinical trial provided an opportunity to understand the onboarding experience of a new SCIG 20% in patients with PIDD.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2017-02, Vol.139 (2), p.AB216-AB216
Hauptverfasser: Gupta, Sudhir, MD, PhD, MACP, Stein, Mark R., MD, FAAAAI, Melamed, Isaac Reuven, MD, Hussain, Iftikhar, Paris, Kenneth, MD, MPH, Engl, Werner, PhD, McCoy, Barbara, PhD, Rabbat, Christopher J., PhD, Yel, Leman, MD, FAAAAI
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Rationale Data from a phase 2/3 North American clinical trial provided an opportunity to understand the onboarding experience of a new SCIG 20% in patients with PIDD.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2016.12.699